Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed using the accompanying table.

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

Abu Dhabi: Abu Dhabi-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the ...

Abu Dhabi’s state-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...